LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX)

Q: What does CUSIP N51517105 represent in this 13F holders report?

CUSIP N51517105 is the security identifier for LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share used to aggregate holder disclosures.

Q: How many institutions held LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share in Q2 2021?

18 institutional investors reported LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share for Q2 2021. Use the holders table for investor-level position and value details.

CUSIP: N51517105

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class: Equity / Common shares, Euro 0.12 nominal value per share
Shares outstanding: 26,019,256
Total 13F shares: 8,772,945
Share change: -449,874
Total reported value: $95,450,000
Price per share: $10.88
Number of holders: 18
Value change: -$5,974,989
Number of buys: 8
Number of sells: 17

Quarterly Holders Quick Answers

What is CUSIP N51517105?
CUSIP N51517105 identifies LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2021
Previous quarter: Q1 2021

Recent filing periods for CUSIP N51517105:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

Institutional Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q2 2021

As of 30 Jun 2021, LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) was held by 18 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 8,772,945 shares. The largest 10 holders included Novo Holdings A/S, Redmile Group, LLC, Nicholas Investment Partners, LP, Nantahala Capital Management, LLC, AXA S.A., SPHERA FUNDS MANAGEMENT LTD., WELLINGTON MANAGEMENT GROUP LLP, Artal Group S.A., Falcon Edge Capital, LP, and MILLENNIUM MANAGEMENT LLC. This page lists 18 institutional shareholders reporting positions in this security for the Q2 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2021 vs Q1 2021 Across Filers

Q1 2021 holders

Q2 2021 holders

Holder diff

-6

Investor	Q1 2021 Shares	Q2 2021 Shares	Share Diff	Share Chg %	Q1 2021 Value $	Q2 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.